Intraventricular Access Device ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
19	Lysosomal storage disease	2

19. Lysosomal storage disease

---

Clinical trials : 854 /  Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02678689 (ClinicalTrials.gov)	February 2016	15/1/2016	A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease	A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease	Jansky-Bielschowsky Disease;Batten Disease;Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2;CLN2 Disease;CLN2 Disorder	Biological: BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1);Device: Intraventricular access device	BioMarin Pharmaceutical	NULL	Active, not recruiting	N/A	17 Years	All	14	Phase 2	United States;Germany;Italy;United Kingdom
2	NCT02485899 (ClinicalTrials.gov)	February 2015	24/4/2015	A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease	A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease	Jansky-Bielschowsky Disease;Batten Disease;Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2;CLN2 Disease;CLN2 Disorder	Biological: BMN 190;Device: Intraventricular Access Device	BioMarin Pharmaceutical	NULL	Completed	3 Years	16 Years	All	23	Phase 1/Phase 2	United States;Germany;Italy;United Kingdom